Skip to main content

Table 3 Mutations selected in viruses with PI resistant proteases during the bevirimat in vitro selections

From: HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat

PI resistant proteases

 

CA

p2

Gag position

359

360

361

362

363

364

365

366

367

368

369

370

371

HXB2 aa

K

A

R

V

L

A

E

A

M

S

Q

V

T

PR-1

n = 5

-

-

-

-

-

V

-

-

-

-

-

-

-

 

-

-

-

-

-

A/V

-

-

-

-

-

-

-

 

-

-

-

V/I

L/M

-

-

-

-

N

-

A

-

 

-

-

-

V/I

-

-

-

-

-

S/N

-

-

T/N

 

-

-

-

-

-

A/V

-

-

-

-

-

-

T/N

PR-2

n = 5

-

-

-

-

-

-

-

-

-

S/N

-

-

-

 

-

-

-

-

-

-

-

-

-

-

-

V/A

-

 

-

-

-

V/I

-

A/V

-

-

-

-

-

-

-

 

-

-

-

V/I

-

-

-

-

-

-

-

-

-

 

-

-

-

-

-

-

-

-

-

-

-

A

-

PR-3

n = 5

-

-

-

V/I

-

-

-

-

-

S/N

-

-

-

 

-

-

-

-

-

A/V

-

-

-

-

-

-

-

 

-

-

-

-

-

V

-

-

-

-

-

-

-

 

-

-

-

-

-

-

-

-

-

S/N

-

V/A

-

 

-

-

-

V/I

-

-

-

-

-

-

-

-

-

PR-4

n = 5

-

-

-

-

-

A/V

-

-

-

-

-

-

-

 

-

-

-

V/I

-

-

-

-

-

-

-

V/A

-

 

-

-

-

V/I

-

-

-

-

-

-

-

-

-

 

-

-

-

V/I

-

-

-

-

-

S/N

-

-

-

 

-

-

-

-

-

-

-

-

-

-

-

A

-

PR-5

n = 5

-

-

-

V/I

-

-

-

-

-

-

-

-

-

 

-

-

-

-

L/M

A/V

-

-

-

-

-

-

-

 

-

-

-

V/I

-

-

-

-

-

-

-

V/A

-

 

-

-

-

-

-

-

-

-

-

-

-

V/L

-

 

-

-

-

-

-

A/V

-

-

-

S/N

-

-

-

PR-6

n = 5

-

-

-

V/I

-

-

-

-

-

S/N

-

-

-

 

-

-

-

V/I

-

A/V

-

-

-

S/N

-

-

-

 

-

-

-

I

-

-

-

-

-

-

-

-

-

 

-

-

-

V/I

-

-

-

-

-

-

-

V/A

-

 

-

-

-

-

-

-

-

-

-

-

-

V/A

-

  1. Schematic representation of the amino acid changes appearing in the CA/p2 region after bevirimat in vitro selection experiments with the PR-1 - PR-6 mutants. In vitro selections with the protease mutants were performed 5 times. Mutations that previously have been identified in vitro as bevirimat resistance mutations are indicated in bold. The QVT-polymorphisms that are associated with a reduced response to bevirimat in vivo are underlined. Previously unknown mutations are printed in italic type. The actual CA/p2 cleavage site is between amino acids 363 and 364.